Zika Virus IgM ELISA

The Native Antigen Company’s Zika Virus IgM ELISA assay is designed for the detection of Zika-specific IgM antibodies in human serum. It is minimally cross-reactive with antibodies to Dengue virus (a closely-related flavivirus), and so can be used to distinguish human anti-Zika antibodies from other flavivirus and infectious disease antibodies.

The assay is currently offered for research studies, and for evaluation for development and registration as a diagnostic tool for detection of Zika virus infection.  Please contact us to discuss your interest in the assay so that we can provide you with the very latest information on kit evaluation and performance.  Beta test kits are available for purchase following completion of an MTA.  

Our Zika Virus IgM ELISA has an assay time of only 4 hours, with specificity and sensitivity both in excess of 95%.  Due to the novel assay format the test displays remarkable levels of specificity, with cross-reactivity to Dengue being minmised.

Zika virus (ZIKV) is a member of the virus family Flaviviridae and the genus Flavivirus, transmitted by Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Zika Forest of Uganda, where the virus was first isolated in 1947. Zika virus is related to Dengue, Yellow Fever, Japanese Encephalitis, and West Nile viruses, and many antibodies (e.g. those produced as a response to infection) cross-react between these viruses. This cross-reaction causes severe problems in identifying individuals seropostive for Zika as the much wider spread background of Dengue infections cause many false positives in most standard serological ELISAs. NAC’s Zika virus antibody capture ELISA uses an in-house manufactured Zika virus-specific antigen to virtually exclude cross reactions and is thus suitable for the accurate detection of serum antibodies to Zika virus, indicating exposure. 

THIS ELISA ASSAY IS FOR RESEARCH USE ONLY. IT IS NOT FOR USE IN DIAGNOSTIC PROCEDURES.